Time course of late rectal toxicity after radiation therapy for prostate cancer

被引:0
作者
K Odrazka
M Dolezel
J Vanasek
M Vaculikova
M Zouhar
J Sefrova
P Paluska
M Vosmik
T Kohlova
I Kolarova
Z Macingova
P Navratil
M Brodak
P Prosvic
机构
[1] Multiscan and Pardubice Regional Hospital,Department of Radiation Oncology
[2] First and Third Faculty of Medicine,Department of Clinical Oncology
[3] Charles University in Prague,Department of Oncology and Radiotherapy
[4] Institute for Postgraduate Medical Education,Department of Nuclear Medicine
[5] Nachod Regional Hospital,Department of Urology
[6] University Hospital Hradec Kralove,Department of Urology
[7] University Hospital Hradec Kralove,undefined
[8] University Hospital Hradec Kralove,undefined
[9] Nachod Regional Hospital,undefined
来源
Prostate Cancer and Prostatic Diseases | 2010年 / 13卷
关键词
rectal toxicity; late toxicity; radiation therapy;
D O I
暂无
中图分类号
学科分类号
摘要
Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1–3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT). The prescription dose was 70 Gy for T1 and T2 patients (n=230) and 74 Gy for patients with locally advanced T3 tumors (n=90). Late rectal toxicity was graded according to the Fox Chase modification of the Radiation Therapy Oncology Group (RTOG) and Late Effects Normal Tissue Task Force (LENT) criteria. The median follow-up time was 6.2 years (range 0.2–10.7 years). At 5 years, the risk for the development of grade 2 and 3 rectal toxicities was 15.6 and 7.0%, respectively. All new cases of grade 2 and 3 rectal toxicities were observed within 5 years after treatment. Prevalence of grade 2 and 3 rectal symptoms showed fluctuation with maximum at 1.5 years and the minor peak at 4.5 years. Toxicity profile changed significantly over time. The proportion of rectal bleeding within grade 2 and 3 toxicity decreased from 85% at 1.5 years to 46% at 4.5 years. Conversely, the proportion of fecal incontinence among grade 2 and 3 rectal symptoms gradually increased (0% at 1.5 years vs 27% at 4.5 years). Late rectal radiation toxicity represents a dynamic process. Rectal bleeding decreases and fecal incontinence increases over time.
引用
收藏
页码:138 / 143
页数:5
相关论文
共 119 条
[1]  
Zelefsky MJ(1999)Long term tolerance of high dose three-dimensional radiotherapy in patients with localized prostate carcinoma Cancer 85 2460-2468
[2]  
Cowen D(2000)Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial Int J Radiat Oncol Biol Phys 48 635-642
[3]  
Fuks Z(2005)Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V Int J Radiat Oncol Biol Phys 62 706-713
[4]  
Shike M(2005)Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68–78 Gy Int J Radiat Oncol Biol Phys 61 1019-1034
[5]  
Burman C(2009)Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy Strahlenther Onkol 185 94-100
[6]  
Jackson A(2002)Evolution of toxicity after conformal radiotherapy for prostate cancer Prostate Cancer Prostatic Dis 5 296-303
[7]  
Storey MR(2008)Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 70 1124-1129
[8]  
Pollack A(2008)Late gastrointestinal morbidity after three-dimensional conformal radiation therapy for prostate cancer fades with time in contrast to genitourinary morbidity Int J Radiat Oncol Biol Phys 70 1478-1486
[9]  
Zagars G(2002)Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 54 1314-1321
[10]  
Smith L(2007)Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control Radiother Oncol 82 160-166